Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1392992
This article is part of the Research Topic Case Reports in Autoimmune and Autoinflammatory Disorders View all 26 articles

Efficacy of steroid therapy in the acute stage of anti-NMDAR and anti-MOG antibody overlapping encephalitis: A case report and literature review

Provisionally accepted
Hikari Kondo Hikari Kondo 1*Yuko Takeuchi Yuko Takeuchi 2Junichi Niwa Junichi Niwa 3Kenji Yoshida Kenji Yoshida 1Naoaki Takemura Naoaki Takemura 1Sachiko Hosoyama Sachiko Hosoyama 1Tomotsugu Kaga Tomotsugu Kaga 1Kimihiko Kaneko Kimihiko Kaneko 4Naoki Mabuchi Naoki Mabuchi 1
  • 1 Department of Neurology, Nagoya Ekisaikai Hospital, Nagoya, Aichi, Japan
  • 2 Department of Neurology, Masuko Memorial Hospital, Nagoya, Japan
  • 3 Department of Neurology, Stroke center, Aichi Medical University, Nagakute, Japan
  • 4 Department of Neurology, Tohoku University, Sendai, Miyagi, Japan

The final, formatted version of the article will be published soon.

    Background: Recently, cases of overlapping encephalitis caused by anti-N-methyl-D-aspartate receptor (anti-NMDAR) and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies have been reported, and their clinical characteristics are gradually becoming clear. Acute-phase treatment typically involves the use of steroids, and although some studies have suggested that steroids can be effective, the extent of their efficacy has not yet been fully explored. Case Presentation: We present the case of a 25-year-old man with anti-NMDAR and anti-MOG antibody overlapping encephalitis who showed considerable improvement after steroid treatment. To gain a deeper understanding of the efficacy of steroids in managing this condition, we conducted a literature review of cases of anti-NMDAR and anti-MOG antibody double-positive encephalitis that were treated with steroids during the acute phase. Thirteen cases were analyzed, including a new case diagnosed at our hospital. All patients showed improvement after receiving steroid treatment in the acute phase. Ten patients did not have any sequelae, and nine of them showed a rapid or major response during the acute phase. In contrast, three patients experienced sequelae (mild cognitive decline, visual impairment, and memory impairment, respectively), with their response to steroids in the acute phase being slow or limited. Relapses occurred in five patients, in one patient during steroid tapering, and in another two patients after cessation of steroids. Conclusion: Steroid therapy can be effective in the acute stage of anti-NMDAR and anti-MOG antibody overlapping encephalitis. A positive prognosis may be expected in patients who experience substantial improvement with steroid therapy during the acute phase.

    Keywords: anti-NMDAR encephalitis, autoimmune encephalitis, Myelin oligodendrocyte glycoprotein (MOG), N-methyl-D-aspartate receptor (NMDAr), overlapping encephalitis, steroid

    Received: 28 Feb 2024; Accepted: 08 May 2024.

    Copyright: © 2024 Kondo, Takeuchi, Niwa, Yoshida, Takemura, Hosoyama, Kaga, Kaneko and Mabuchi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hikari Kondo, Department of Neurology, Nagoya Ekisaikai Hospital, Nagoya, 454-0854, Aichi, Japan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.